Trial Profile

A Phase 2 proof-of-concept trial of BRB-002 in patients with established atherosclerosis

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BRB-002 (Primary)
Indications Atherosclerosis
Focus Proof of concept; Therapeutic Use
Acronyms MATADOR

Most Recent Events

02 Jun 2025 According to Bitterroot Bio media release, company expects to report initial results from the MATADOR Phase 2a study by year-end 2026.
02 Jun 2025 According to Bitterroot Bio media release, company announced the dosing of the first patient in its proof-of-concept MATADOR Phase 2a study in Australia
02 Jun 2025 Status changed from planning to recruiting, according to Bitterroot Bio media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com